Download presentation
Presentation is loading. Please wait.
Published byΌσιρις Ζυγομαλάς Modified over 6 years ago
1
Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non–Small Cell Lung Cancer
Hiromi Furuta, MD, PhD, Tatsuya Yoshida, MD, PhD, Junichi Shimizu, MD, PhD, Natsuo Tomita, MD, PhD, Yasushi Yatabe, MD, PhD, Toyoaki Hida, MD, PhD Journal of Thoracic Oncology Volume 12, Issue 11, Pages (November 2017) DOI: /j.jtho Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions
2
Figure 1 Computed tomography scan of muscle metastatic and primary lung lesions before (A and B) and 2 months after the initiation of nivolumab treatment (C and D). Journal of Thoracic Oncology , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions
3
Figure 2 Dermatitis on the irradiated field at 2 weeks, 1.5 months, and 3 months after the start of nivolumab treatment (A, B, and C, respectively). Journal of Thoracic Oncology , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions
4
Figure 3 Dose distribution of radiotherapy to the muscle metastatic lesion. Journal of Thoracic Oncology , DOI: ( /j.jtho ) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.